DrugBank
MAY 15, 2024
In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets. One approach is to look beyond the traditional drug molecule.
Sygnature Discovery
SEPTEMBER 14, 2023
Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
NOVEMBER 27, 2023
These API-derived nitrosamines are referred to as Nitrosamine Drug Substance Related Impurities (NDSRIs) and represent an unprecedented development with manufacturing, quality, and product safety implications. In a study of more than 12,000 small molecule drugs , researchers found 40.4%
Agency IQ
AUGUST 11, 2023
In a study of more than 12,000 small molecule drugs , researchers found 40.4% This means that entire classes of critical drugs (like ACE inhibitors and beta blockers) containing secondary or tertiary amine moieties in their API molecular structures are technically nitrosamine precursors.
The Pharma Data
JUNE 11, 2025
By leveraging large-scale genomic datasets and functional assays in human cardiomyocytes, researchers from Bayer and the Broad Institute are working to map the complex gene networks that drive disease progression in DCM and other cardiovascular disorders.
Drug Target Review
FEBRUARY 11, 2025
Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. Todays small molecules are far larger, more complex, and chase highly specific (and difficult to hit) targets, thereby increasing the chances of undesired side effects.
Expert insights. Personalized for you.
Let's personalize your content